Effects of Metformin on Rosiglitazone-Induced Cardiac Hypertrophy in Mice

• Lee Hsiu-Hao

  Department of Internal Medicine, Zhongxing Branch of Taipei City Hospital

• Yeh Ching-Hua

  Graduate Institute of Medical Sciences, Chang Jung Christian University Department of Medical Research, Chi-Mei Medical Center

• Chen Yu-Tai

  Department of Nursing, Shin-Kong Memorial Hospital

• Chi Tzong-Cherng

  Graduate Institute of Medical Sciences, Chang Jung Christian University

• Cheng Juei-Tang

  Graduate Institute of Medical Sciences, Chang Jung Christian University Department of Medical Research, Chi-Mei Medical Center Department of Pharmacology, College of Medicine, National Cheng Kung University

• Lo Shih-Hsiang

  Department of Internal Medicine, Zhongxing Branch of Taipei City Hospital

抄録

Thiazolidinediones (TZD) can cause adipose tissue accumulation and myocardial hypertrophy. This study aimed to determine if combined Metformin (Glucophage) and Rosiglitazone (Avandia) could reduce the risk of heart failure caused by Rosiglitazone in BALB/c mice. BALB/c mice were treated with oral Rosiglitazone/Metformin twice daily for four weeks. Metformin or Rosiglitazone alone and non-treated mice acted as double control. Myocardial hypertrophy and associated side effects of the combined therapy were determined through isolated heart and body weights. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were applied to evaluate expression of sulfonylurea receptor 2A (SUR2A) and Kir 6.2. The activities of peroxisome proliferator activated receptor α (PPARα) in the myocardium were also observed. Rosiglitazone/Metformin decreased body weight gain and food intake, and inhibited an increasing adipose ratio but did not reduce myocardial hypertrophy. Rosiglitazone increased Kir6.2/SUR2A, Kir6.2/SUR2B, and PPARα gene expression. The Rosiglitazone/Metformin combination further increased these gene expressions, especially PPARα. Metformin inhibits obesity but has no effect in reducing myocardial hypertrophy caused by Rosiglitazone. Whether Metformin can reduce side effects of TZDs in humans warrants further study.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 33 (9), 1506-1510, 2010

  公益社団法人 日本薬学会

キーワード

• Metformin
• Rosiglitazone
• myocardial hypertrophy
• obesity
• adipose accumulation

詳細情報

• CRID: 1390001204626562816
• NII論文ID: 130000322347
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.33.1506
• ISSN: 13475215
• ISSN: 09186158
• NDL書誌ID: 10796800
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I10796800
• Web Site: http://www.jstage.jst.go.jp/article/bpb/33/9/33_9_1506/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2011175551
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可